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Abstract 
Aims: In recent years there has been an increase in the number of biomarkers in heart 
failure(HF).  The clinical role for these novel biomarkers in combination is not clear. 
Methods: The following novel biomarkers were measured from 628 patients recently 
hospitalised with decompensated HF; mid regional pro-adrenomedullin(MR-proADM), 
mid regional pro-atrial natriuretic peptide(MR-proANP), copeptin, high sensitivity 
cardiac troponin T(hs-cTnT), ST2, galectin-3, cystatin C, combined free light 
chains(cFLC) and high sensitivity C-reactive protein(hsCRP). The incremental 
prognostic value of these novel biomarkers was evaluated within an extensive model 
containing established predictors of mortality. 
Results: During a mean(SD) follow-up of 3.2(1.5) years, 290(46%) patients died. 
Elevated concentrations of all of the novel biomarkers were associated with an increased 
unadjusted risk of mortality but only two-thirds were independent predictors following 
multivariable analysis. Using dichotomized cut-points from ROC analysis, MR-proADM, 
hs-cTnT, cFLC, hsCRP and ST2 remained independent predictors of mortality. Further 
dichotomization into low(0-2 elevated biomarkers) or high(at least 3 of the 5 biomarkers 
elevated) risk groups provided greatest incremental prognostic value(HR 2.20; 95%CI, 
1.37 to 3.54; p=0.001) and improved the predictive power of the model(C-statistic 0.730 
from 0.721, NRI 32.5%). 
Conclusion: The novel biomarkers included in this study added little, if any, incremental 
prognostic value on their own to an extensive model containing established predictors of 
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mortality.  However, following dichotomization, 5 of the novel biomarkers provided 
incremental prognostic value. There was a clear gradient in the risk of death with 
increasing numbers of elevated novel biomarkers; the presence of at least 3 identifying 
patients at greatest mortality risk. 
  
Key words: Heart failure, prognosis, novel biomarkers, risk stratification 
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Introduction 
An accurate means of predicting mortality risk in heart failure (HF) would allow 
clinicians to have an honest and informed discussion with patients regarding their 
prognosis (1). Those at low risk could be reassured.  Those at high risk of dying could be 
considered for complex devices (including an implantable cardioverter-defibrillator - 
ICD), cardiac transplantation, or optimal end of life care (2). 
In recent years there has been a remarkable increase in the number of biomarkers 
available in HF (3), many of which have been thought to hold prognostic potential (4, 5). 
Yet understanding of their relevance and clinical value for patients with HF in real world 
populations remains limited. Different biomarkers represent different pathophysiological 
pathways.  The use of multiple biomarkers (that reflect different pathophysiological 
processes) in combination may be of greater prognostic value than using them in 
isolation. Many of these putative prognostic markers have been tested in small, selected 
populations with limited multivariable analyses. To date, no study has evaluated the 
prognostic value of multiple novel biomarkers, representing all the known 
pathophysiological pathways, in combination in a real-life, unselected chronic HF 
population.  
We studied the prognostic value of several contemporary biomarkers, spanning several 
pathophysiological pathways in HF, in a prospective cohort of patients recently 
hospitalised with decompensated HF. Candidate biomarkers from several classes were 
studied: (i) neurohormonal (mid regional pro-adrenomedullin [MR-proADM], mid 
regional pro-atrial natriuretic peptide [MR-proANP] and copeptin), (ii) myocyte injury 
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and apoptosis (high sensitivity cardiac troponin T [hs-cTnT]), (iii) myocyte stress and 
remodelling (ST2), (iv) extracellular-matrix remodelling (galectin-3), (v) extra-
cardiac involvement (cystatin C and combined free light chains [cFLC]) and (vi) 
inflammation (cFLC and high sensitivity C-reactive protein [hsCRP]). 
 
Methods 
Our study was approved by the Local Ethics Committee and complied with the 
Declaration of Helsinki. All patients provided written informed consent. 
  
Study design 
The study design has previously been reported (6). Briefly, we enrolled 1003 near-
consecutive patients with decompensated HF from three hospitals and defined HF 
according to the criteria of the European Society of Cardiology (7).  Eligible patients 
were required to be 18 years or older and an elevated B-type natriuretic peptide (BNP 
>100pg/ml) was mandatory. The main exclusion criteria were: primary presentation with 
myocardial infarction (MI), concurrent systemic disease likely to result in reduced life 
expectancy or cognitive impairment. Attendance for the study visit occurred 1 month 
post-discharge. Of 1003 patients originally enrolled, 648 patients (65%) attended the 
study visit. Failure to attend was due to death (n=115, 11%), deterioration in health 
(n=73, 7%) or withdrawal of consent (n=167, 17%).  
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Laboratory measurements – biomarkers studied 
Whole blood was drawn from venepuncture into serum and plasma vacutainers. Samples 
were processed immediately by centrifugation at 3000g for 15 minutes and serum and 
plasma fractions were aliquoted for storage at -80°C until assay. Copeptin, MR-proADM 
and MR-proANP were measured on an automated BRAHMS Kryptor analyzer 
(BRAHMS, Hemel Hempstead, UK) with limits of detection 4.8pmol/l, 0.05nmol/l and 
6pmol/l, respectively. Assay precision (coefficient of variation [CV]) ranged between 
2.2-3.2%, 3.5-6.1% and 2.1-13.5% for MR-proANP, MR-proADM and copeptin, 
respectively. Hs-cTnT was measured on an automated e411 (Roche, Burgess Hill, UK), 
with a limit of detection of 3ng/ml and CV range of 1.2-5.5%. ST2 was measured using 
an enzyme-linked immunosorbent assay (ELISA) (R&D systems, Oxon, UK), with a 
limit of sensitivity of 0.1ng/ml and CV range of 4.4-10.6%.  Galectin-3 was measured in 
our laboratory using an ELISA (provided by BG Medicine, MA, USA) according to the 
manufacturer’s instructions with a limit of sensitivity of 1.3ng/ml and CV range of 3.2-
6.2%. cFLC were measured by turbidimetry using the Combylite™ immunoassay on a 
SPAPLUS® automated analyzer (The Binding Site Group, Ltd, Birmingham, UK), with a 
limit of quantification of 0.63mg/l and CV range of 5.5-14.4%. Cystatin C was measured 
on a SPAPLUS® automated analyzer (The Binding Site Group, Ltd, Birmingham, UK), 
with a limit of detection of 0.4mg/l and CV range of 5.4-9.4%.  hsCRP was measured 
using a Siemens immunoassay on a Siemens BN II™ nephelometer, with a limit of 
detection of 0.03mg/ml and CV range of 2.5-5.7. 
Plasma BNP was measured using an Abbott Architect assay (Abbott Diagnostics, 
Maidenhead, UK). Along with BNP, all other biochemical and hematological assays were 
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performed in local National Health Service laboratories in Glasgow, UK, and these 
assays all performed adequately in the relevant national external quality assurance 
schemes. 
 
Left ventricular ejection fraction 
Left ventricular ejection fraction (LVEF) was measured by two-dimensional 
echocardiography and reduced systolic function was defined as LVEF <50% (8). 
Analysis was performed offline, using the biplane method of discs (modified Simpson’s 
rule) by a single operator blinded to patient information. 
 
Follow-up 
All patients consented to be “flagged” with the Information Services Division (ISD) of 
the Scottish Health Service for data on in-hospital and out-of hospital deaths, held by the 
General Register Office for Scotland. The primary outcome measure was all-cause 
mortality.  
 
Statistical Analysis 
Survival time was calculated from the date of the study visit (between 16th January 2007 
and 6th March 2009) until death or censoring at 31st August 2012. Univariate Cox 
regression analyses were performed for all novel biomarkers. All continuous variables 
were transformed as appropriate to normalize their distributions. The incremental 
prognostic value of each novel biomarker was evaluated using Cox proportional hazard 
models including established predictors of outcome in heart failure. The predictors 
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included in the baseline model were selected from the clinical model derived by the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity 
(CHARM) investigators (9) and routine hematological and biochemical variables 
predictive of outcome in the subsequent CHARM analyses (10,11). These established 
predictors of outcome included: age, sex (men vs women), smoking habit (current vs 
none or past), history of HF for more than 2 years, NYHA class (III/IV vs I/II), LVEF, 
medical history (MI, diabetes mellitus, chronic obstructive pulmonary disease, peripheral 
arterial disease), left bundle branch block (LBBB) on electrocardiogram, heart rate, 
systolic blood pressure, body mass index, peripheral edema, bilirubin, urate, creatinine, 
hemoglobin, glycosylated hemoglobin, lymphocytes and red cell distribution width 
(RDW). B-type natriuretic peptide (BNP) was also included in the baseline model. 
Multivariable Cox regression analyses were performed for each novel biomarker in turn. 
Model performance was assessed using Harrel’s C-statistic (12). The proportional 
hazards assumption was assessed using Shoenfield residuals. Each biomarker was 
dichotomized using receiver operating characteristic (ROC) curves with cut-points 
determined using the Kaplan Meier method (13). Univariate and multivariable analyses 
were performed as before using the dichotomized results. A p-value d 0.1 was considered 
significant. The effect of multiple elevated biomarkers was then evaluated for 1, 2 and 3 
or more elevated biomarkers using univariate and multivariable analysis. Kaplan-Meier 
survival curves were constructed to illustrate survival of patients according to number of 
elevated novel biomarkers, dichotomized from ROC analysis. Curves were compared 
using the log rank test. All statistical analyses were performed using R version 2.15.0 or 
above. The net reclassification index (NRI) (14), adapted for use in survival models (15), 
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was used to assess if elevated levels of 3 or more novel biomarkers improved the 
prediction of outcome, in addition to the multivariable model. Internal validation was 
performed by bootstrapping, using Somers’ Dxy rank correlation as the marker of 
validation, to evaluate the predictive performance of the data. 
 
Results  
Of 648 patients completing the study visit, 628 (97%) had analysis of the entire set of 
novel biomarkers performed. The mean (SD) age of the overall cohort was 71 (11) years 
and 367 (58%) were male. The baseline clinical characteristics, including novel 
biomarker results, are presented in Table 1 for the overall cohort. 
 
Overall survival following hospital admission with decompensated heart failure 
The mean (SD) follow-up was 3.2 (1.5) years. Of the 628 patients with novel biomarker 
measurements, 290 (46%) died during the follow-up period. The multivariable analysis 
for the base model is shown in Table 2. 
 
Unadjusted outcomes according to novel biomarker concentration 
Elevated concentrations of all of the novel biomarkers were associated with a higher 
unadjusted risk of mortality (Table 3). This heightened risk was particularly evident in 
patients with elevated log [MR-proADM] and log [cystatin C] concentrations, with more 
than double an increased unadjusted risk (hazard ratios [HR] 2.83 and 2.72, respectively). 
 
Multivariable analysis with the novel biomarkers as continuous variables 
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The multivariable analyses with each biomarker added individually to the baseline model 
are displayed in Table 4 (the full models are shown in Table 1 of the Appendix). In the 
base model, almost half of the predefined variables were independent predictors of an 
increased risk of death with a C-statistic for the overall model of 0.721 (Table 2).  In the 
multivariable analyses, MR-proADM, hs-cTnT, ST2, cFLC, hsCRP and cystatin C 
remained independent predictors of mortality (defined as p d 0.1).  Copeptin, MR-
proANP and galectin-3 failed to add incremental prognostic value to the base model. 
Elevated MR-proADM and cystatin C concentrations were associated with the highest 
HRs, with almost double the mortality risk per log[unit] increase (HR 1.81 and p<0.01; 
HR 1.99 and p=0.05, respectively). In terms of adding to the prognostic strength of the 
overall model, hsCRP had the greatest effect (HR 1.21, p<0.001) increasing the C-
statistic from 0.721 to 0.727. 
 
Multivariable analyses using dichotomized biomarkers 
Each biomarker was dichotomized using receiver operating characteristic (ROC) curves; 
the cut-points are displayed in Table 3. Univariate and multivariable analyses were 
performed as before using the dichotomized results (Tables 3 and 4). The unadjusted 
outcomes were similar to the continuous values, with higher levels of the entire set of 
dichotomized novel biomarkers associated with a higher risk of mortality (all p values 
<0.001).  Most biomarkers were associated with an even greater risk of mortality as a 
dichotomized variable, than as a continuous variable, with MR-proADM and hs-cTnT 
associated with more than double the risk of death. Following multivariable analysis, 
MR-proADM, hs-cTnT, ST2, cFLC and hsCRP remained independent predictors of 
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mortality (defined as p d 0.1), with increased adjusted mortality risk ranging from 29-
64% for these 5 novel biomarkers. In terms of adding to the prognostic strength of the 
overall model, cFLC had the greatest effect (HR 1.64, p<0.001) increasing the C-statistic 
from 0.721 to 0.729. 
 
Number of elevated novel biomarkers - prognostic significance 
Of 628 patients, 130 (20.7%) had none of the 5 significant novel biomarkers (MR-
proADM, hs-cTnT, ST2, cFLC and hsCRP) elevated above the ROC cut-points and 251 
(40%) had one or two elevated biomarkers. A similar proportion (n=247; 39%) of 
patients had ≥3 elevated biomarkers.  Of these 247 patients, a similar number of patients 
had 3 (n=113, 45.7%) or 4 (n=103, 41.7%) elevated biomarkers, whilst few patients had 
an elevation of all 5 biomarkers (n=31, 12.6%). Of those with ≥3 elevated biomarkers, 
MR-proADM was elevated in nearly all cases (n=230, 93.1%) with hs-cTnT being the 
next frequently elevated biomarker (n=208, 84.2%). Similar proportions of patients had 
elevated hsCRP (n=180, 72.9%) and cFLC (n=172 (69.6%) whilst less than half of all 
patients had an elevated ST2 (n=116, 47.0%). The breakdown of all combinations of ≥3 
elevated biomarkers are displayed in the appendix (Appendix Table 3). Survival curves 
demonstrated an increasing unadjusted mortality risk with increasing numbers of elevated 
biomarkers (Figure 1a), with a clear step up in mortality risk for patients with three or 
more elevated biomarkers (Figure 1b) who had almost four times the risk of death 
compared to patients with no elevated biomarkers - 3 year mortality rate for number of 
biomarkers elevated: 0 = 18.5%, 1 = 25.7%, 2 = 33.0% and e3 = 51.8% (Table 5). The 
presence of 3 or more elevated biomarkers remained an independent predictor of higher 
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mortality risk following multivariable analysis, with over double the mortality risk 
compared to patients without elevation of any of the 5 biomarkers (HR 2.10; p=0.002) 
(full multivariable model in Appendix Table 4).  
Net reclassification index (NRI) for the addition of 3 or more elevated biomarkers to the 
multivariable model, at 3 years follow up, was high with an overall NRI of 0.33 (95% CI 
0.16, 0.49; p<0.001). Validation by bootstrap (300 replicates) resulted in an optimism of 
2%. 
 
There were many differences in clinical characteristics according to number of 
biomarkers elevated (Appendix Table 5). Compared with patients with no elevated or 1-2 
elevated biomarkers, patients with 3 or more elevated biomarkers were older, more often 
male and to have a previous diagnosis of HF. They were more symptomatic, with a 
greater proportion of patients in NYHA class III/IV and more had peripheral oedema. 
Patients with 3 or more elevated biomarkers also had more comorbidities such as 
myocardial infarction, hypertension, diabetes mellitus and atrial fibrillation. 
 
Discussion 
We compared the prevalence and prognostic significance of a range of novel biomarkers, 
individually and collectively, in a group of patients recently hospitalized with 
decompensated HF. Our patients had a high mortality rate, with 46% of the cohort 
deceased by the end of the follow-up period. The first notable, but perhaps unsurprising, 
finding was that all of these biomarkers individually were predictors of unadjusted 
mortality risk in this relatively unselected cohort. However, only half of the novel 
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biomarkers were independent predictors of mortality when added to a multivariable 
prognostic model containing established predictors of mortality risk, including BNP. 
Copeptin, MR-proANP and galectin-3 failed to add any incremental prognostic value to 
this base model. The second important finding was that, following dichotomization of the 
novel biomarkers, the presence of at least 3 elevated biomarkers identified patients at 
greatest risk of death. The predictive value of 3 or more elevated biomarkers remained 
after adjustment for other prognostic factors in the multivariable model - such patients 
had more than double the adjusted risk of death compared to patients with no elevation of 
any of these novel biomarkers. Furthermore, elevation of at least 3 novel biomarkers 
improved net reclassification in addition to an extensive multivariable model. 
 
Novel biomarkers individually have limited incremental prognostic value  
Heart failure is a complex syndrome involving many pathophysiological pathways, the 
components of which can be represented by various biomarkers. The main recognized 
pathways are the neurohormonal, cardiomyocyte injury, cardiomyocyte stress, 
remodelling and inflammatory processes, as well as extra-cardiac influences. To our 
knowledge this is the first study to study the prognostic value of multiple novel candidate 
biomarkers together, with representation from all of the main pathophysiological 
pathways.  
 
The baseline model had reasonably good predictive power (C-statistic higher than 0.7) 
prior to the addition of any of the novel biomarkers as continuous variables. Although 
MR-proADM and ST2 provided some incremental prognostic information to the baseline 
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model, the importance of inflammation and extra-cardiac processes was also apparent 
with hsCRP and cFLC demonstrating independent predictive value. However, 
individually, these biomarkers only modestly improved the predictive power of the 
model. This may suggest that evaluation of one pathophysiological pathway may not give 
sufficient prognostic information to be clinically valuable (or that particular pathways 
may be more or less important in particular individuals). 
 
Dichotomized cut-points – similar values to published thresholds of risk 
The potential clinical value of the novel biomarkers was more apparent using 
dichotomized cut-points from the ROC analysis, especially when more than one 
biomarker was evaluated simultaneously (see below). Dichotomization into low- (0-2 
elevated biomarkers) or high- (at least 3 elevated biomarkers) risk groups provided 
greatest incremental prognostic value statistically, and possibly a more clinically 
meaningful result for the practicing clinician. The cut-points yielded from ROC analysis 
were similar to the thresholds of risk that have previously been published for the 
individual biomarkers. A previous study of copeptin, MR-proADM and MR-proANP in a 
small group of patients with acute decompensated HF, (n=137), found similar 
concentrations to the present study for identifying low and high risk of 1 year mortality 
(16). Our dichotomized cut-point for hs-cTnT (21.9pg/ml) is extremely close to the level 
(20pg/ml) that has previously been shown to identify patients with acute decompensated 
HF at greatest risk of all-cause mortality (17). In that study patients hospitalized with HF 
secondary to acute myocardial infarction were also excluded, akin to our study, and 
follow-up exceeded one year. A large, multicenter study of patients with chronic systolic 
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HF (18) found median values of ST2 similar to our dichotomized cut-point (27.5ng/ml vs 
28.4ng/ml). Patients in the highest tertile (ST2>36.3ng/ml) were at greatest risk of 
mortality or cardiac transplantation, over a similar median follow-up period to our study. 
hs-CRP has recently been studied in a large, randomized controlled clinical trial in acute 
decompensated HF (19). Interestingly, hs-CRP levels that had increased from baseline 
during hospitalization to 30 days post-discharge were associated with a greater 180-day 
mortality but elevated levels during admission were not.  Although a threshold of risk for 
hs-CRP at 30-days post hospitalization is not reported, the median value (4.57mg/l) is 
close to our dichotomized cut-point (6.0mg/l). We have recently reported the incremental 
prognostic value of cFLC in HF (20), although little else is known about the potential role 
of this biomarker in patients with HF. 
 
‘The old and the new’ – a simple multi-marker approach  
An elevation of at least three out of five of the novel biomarkers significant in the 
dichotomized analysis (MR-proADM, hs-cTnT, ST2, cFLC and hsCRP) provided 
incremental prognostic value when added to a multivariable model containing established 
predictors of mortality in patients with HF, including BNP. Few novel markers have 
previously added incremental predictive information to comprehensive multivariable 
models containing BNP. Of particular importance in our study was MR-proADM, which 
was elevated in nearly all (93%) patients at greatest mortality risk (3 or more elevated 
biomarkers), and hs-cTnT that was elevated in the vast majority of cases (84%); hsCRP 
was also commonly (in 73%) elevated in these patients, as were cFLCs (70%). As 
mentioned earlier, individual biomarkers, or clusters of biomarkers, may potentially 
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identify the pathophysiological pathways which are most important in determining 
outcome in HF. However, hs-cTnT is arguably a non-specific marker of myocyte necrosis 
that is not specific to any injurious mechanism. The precise source of MR-proADM and 
stimuli for its production are uncertain, although the major source of this peptide may be 
the blood vessels. 
 
Potential future role for multiple biomarkers in the management of HF? 
All of the biomarkers in this study were measured using simple, readily available assays. 
In combination five of the novel biomarkers, as dichotomized variables, were powerful 
predictors of mortality risk, with an elevation of three or more biomarkers stratifying 
those at greatest risk. Incorporation of these five biomarkers into the routine blood tests 
that are regularly measured in patients with HF would help identify those at greatest risk. 
This may aid clinicians with the difficult decisions surrounding the management of such 
high-risk patients. On the other hand, identifying patients with no, or few, elevated 
biomarkers who are at lower risk may help reassure both clinicians and patients. From a 
practical perspective, future creation of a single panel assay to measure all five of these 
novel biomarkers together would be more efficient for the practicing clinician. Finally, 
the use of these novel biomarkers in any clinical decision making process would first 
require prospective testing in a randomized controlled clinical trial in a well-defined, 
representative population of patients with HF.  
 
Study limitations  
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Only single baseline measurements of the novel biomarkers were available for the 
patients in this study. Longitudinal monitoring of these biomarkers may be even more 
useful for risk stratification and identifying patients who remain at particularly high risk. 
Our patients were studied one month post-hospitalization for decompensated HF and 
many of these biomarkers may differ between acutely decompensated and chronically 
stable patients (and the patients in this study were a survivor cohort). We did not have a 
validation cohort. Non-fatal outcomes and cause of death were not available.  
 
Conclusions 
The novel biomarkers included in this study added little, if any, incremental prognostic 
value individually, when added to a prognostic model containing established clinical 
predictors and BNP.  However, following dichotomization, five of the novel biomarkers 
provided incremental prognostic value. There was a clear gradient in the risk of death 
with increasing numbers of elevated novel biomarkers; the presence of at least three 
elevated novel biomarkers identifying patients at greatest mortality risk. Of potential 
clinical value to physicians is the creation of a single panel assay to measure these five 
biomarkers and incorporate this information into a risk stratification tool containing the 
other clinical variables identified in this study to improve prognostication for patients 
with HF. 
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Figure legends 
 
Figure 1a: Survival curves for all-cause mortality stratified by number of biomarkers 
elevated (0-5) using dichotomized cut-points from the ROC analysis. Kaplan-Meier 
analyses show an increasing gradient of risk with increasing number of elevated 
biomarkers (p<0.0001). 
 
Figure 1b: Survival curves for all-cause mortality stratified by numbers of biomarkers 
using dichotomized cut-points from the ROC analysis in combination. Kaplan-Meier 
analyses show patients with 3 or more elevated biomarkers are at greatest risk compared 
to those with none, 1 or 2 elevated biomarkers (p<0.0001) 
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Figure 1a: Kaplan-Meier plots for number of elevated biomarkers individually 
 
Figure 1b: Kaplan-Meier plot for number of elevated biomarkers in combination 
 26 
Table 1: Baseline characteristics overall  
 
 Overall 
(n=628) 
 
 
Demographic characteristics 
Age (years) 70.8 (10.6) 
Male sex 367 (58.4) 
Current smoker 137 (21.8) 
Heart failure status 
Previous diagnosis HF 273 (43.5) 
HF > 2years 194 (30.9) 
NYHA  III /  IV (v I/II) 208 (33.1) 
LVEF (%) 40.1 (12.1) 
LVEF < 50% 466 (77.4) 
Peripheral oedema 421 (67.0) 
Medical history 
MI 271 (43.2) 
Hypertension 404 (64.3) 
Diabetes mellitus 195 (31.1) 
AF 334 (53.2) 
COPD 177 (28.2) 
PAD 102 (16.2) 
Rheumatoid arthritis 17 (2.7) 
Connective tissue disease 12 (1.9) 
Physiological measurements 
HR (beats per min) 77.1 (15.6) 
SBP (mmHg) 130.9 (23.4) 
DBP (mmHg) 67.8 (13.2) 
BMI (kg/m2) 28.6 (6.7) 
LBBB 120 (19.1) 
Medical therapies  
Diuretic 603 (96.0) 
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 Overall 
(n=628) 
 
ACEI or ARB 501 (79.8) 
Beta blocker 416 (66.2) 
MRA 84 (13.4) 
Laboratory measurements 
BNP (pg/ml) 393 [201-796] 
Urea (mmol/l) 9.7 (5.1) 
Creatinine (µmol/l) 117 (44) 
eGFR (ml/min/1.73m2) 50 (18) 
eGFR <60ml/min/1.73m2 337 (54) 
eGFR <30ml/min/1.73m2 50 (8.0) 
Bilirubin (µmol/l) 11.6 (8.0) 
Urate (mmol/l) 0.47 (0.14) 
HbA1c (%) 6.3 (1.3) 
Haemoglobin (g/dL) 12.5 (2.0) 
White cell count (x109/L) 7.9 (2.4) 
RDW (%) 15.6 (2.5) 
Lymphocytes (x109/L) 1.9 (1.3) 
Novel biomarkers  
Copeptin (pmol/l) 14.4 [4.7-33.1] 
MR-proADM (nmol/l) 1.1 [0.9-1.5] 
MR-proANP (pmol/l) 204.5 [125.8-320.2] 
hs-cTnT (pg/ml) 21.1 [13.3-33.6] 
ST2 (ng/ml) 19.9 [15.3-25.7] 
Galectin-3 (ng/ml) 19.7 [15.3-25.7] 
cFLC (mg/l) 41.9 [29.5-62.2] 
hsCRP (mg/l) 4.6 [2.0-10.1] 
Cystatin C (mg/l) 1.6 [1.3-2.1] 
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Values in parentheses are standard deviations for continuous variables or percentages for 
discrete variables. Values in square brackets are interquartile range for median results.  
 
ACE indicates angiotensin-converting enzyme; AF = atrial fibrillation; ARB = 
angiotensin receptor blocker; BMI = body mass index;  BNP = B-type natriuretic peptide; 
cFLC = combined free light chains; COPD = chronic obstructive pulmonary disease; 
DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; HBA1c = 
glycosylated haemoglobin; HR = heart rate; hsCRP = high-sensitivity C-reactive protein; 
hs-cTnT = high-sensitivity cardiac troponin T; LVEF = left ventricular ejection fraction; 
MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist; MR-proADM 
= mid regional pro-adrenomedullin; MR-proANP = mid regional pro-atrial natriuretic 
peptide; NYHA = New York Heart Association; PAD = peripheral arterial disease; RDW 
= red cell distribution width; SBP = systolic blood pressure 
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Table 2: Multivariable analysis – base model 
 
Variable 
 
HR (95% CI) p value 
 
LVEF per 5% decrease < 50 
BMI per unit decrease < 30 
Age per 10 year 
Sex (Female) 
Diabetes 
HF > 2 years 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PAD 
log lymphocytes (per log unit change) 
HbA1c (per %) 
COPD 
Creatinine (per µmol/l) 
log RDW (per log unit change) 
Hemoglobin (per g/dl) 
Urate (per mmol/l) 
log Bilirubin (per log unit change) 
log BNP (per log unit change) 
 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002 
C-statistic 0.721 
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Table 3: Univariate Cox regression analysis for the novel biomarkers as continuous 
and dichotomized variables 
 
 Continuous variable Dichotomized variable 
Biomarker 
(**) 
HR† (95% CI) p value 
 
HR (95% CI) p value 
 
Copeptin 
(>16.4 pmol/l, 46.7%) 
1.40 (1.25, 1.58) < 0.001 1.90 (1.50, 2.40), p = < 0.001 
MR-proADM 
(>1.1 nmol/l, 53.3%) 
2.83 (2.19, 3.66) < 0.001 2.41 (1.88, 3.10), p = < 0.001 
MR-proANP 
(>283.0 pmol/l, 32.3%) 
1.61 (1.35, 1.92) < 0.001 1.87 (1.48, 2.36), p = < 0.001 
hs-cTnT 
(>21.9 ng/ml, 48.2%) 
1.81 (1.57, 2.08) < 0.001 2.66 (2.08, 3.39), p = < 0.001 
ST2 
(>28.4 ng/ml, 26.1%) 
1.53 (1.23, 1.90) < 0.001 1.74 (1.36, 2.22), p = < 0.001 
Galectin-3 
(>17.3 ng/ml, 61.5%) 
1.78 (1.35, 2.35) < 0.001 1.69 (1.31, 2.17), p = < 0.001 
cFLC 
(>51.8 mg/l, 34.4%) 
1.69 (1.42, 2.00) < 0.001 1.98 (1.57, 2.50), p = < 0.001 
hsCRP 
(>6.0 mg/l, 40.4%) 
1.28 (1.16, 1.41) < 0.001 1.67 (1.32, 2.10), p = < 0.001 
CystatinC 
(>1.6 mg/l, 52.1%) 
2.72 (1.98, 3.74) < 0.001) 2.00 (1.57, 2.54), p = < 0.001 
† Per log unit change ** ROC cut-point for dichotomized value, % of cohort with elevated 
value
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Table 4: Multivariable Cox regression analysis and C-statistics for the novel biomarkers as continuous and dichotomized 
variables 
 Continuous variable  Dichotomized variable 
Biomarker HR†(95%CI) p value (C-statistic)  HR(95%CI) p value (C-statistic) 
Copeptin 0.99 (0.85, 1.15) 0.849 (0.721) 1.06 (0.80, 1.40) 0.711 (0.722) 
MR-proADM 1.81 (1.16, 2.84) 0.009 (0.724) 1.40 (1.00, 1.95) 0.052 (0.722) 
MR-proANP 0.84 (0.65, 1.08) 0.169 (0.722) 0.98 (0.72, 1.33) 0.879 (0.722) 
hs-cTnT 
 
1.20 (0.98, 1.48) 0.075 (0.723) 
 
1.48 (1.11, 1.99) 0.008 (0.723) 
 
ST2 1.31 (1.04, 1.65) 0.024 (0.721) 1.29 (0.99, 1.68) 0.060 (0.722) 
Galectin-3 1.23 (0.86, 1.78) 0.257 (0.721)  1.21 (0.90, 1.62) 0.208 (0.722) 
cFLC 1.37 (1.08, 1.74) 0.011 (0.725) 1.64 (1.22, 2.19) <0.001 (0.729) 
hsCRP 1.21 (1.09, 1.35) <0.001 (0.727) 1.43 (1.10, 1.84) 0.007 (0.724) 
CystatinC 1.99 (1.00, 3.98) 0.051 (0.724) 1.13 (0.81, 1.57) 0.484 (0.721) 
 
† Per log unit change
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Table 5: Cox regression analysis for the number of elevated dichotomized biomarkers (0 = reference)  
 Univariate analysis Multivariable analysis 
Biomarker HR (95% CI) p value  HR (95% CI) p value  
1 
 
1.38 (0.88, 2.17) 0.162 
 
1.02 (0.63, 1.65) 0.938 
2 
 
1.92 (1.23, 2.99) 0.004 
 
1.35 (0.82, 2.20) 0.235) 
e  3 
 
3.88 (2.67, 5.65) < 0.001) 2.20 (1.37, 3.54) 0.001 
 
 
 
 33 
Appendix Tables 
 
Table 1: Full multivariable analyses with the addition of each novel biomarker individually  
 
Base Copeptin MR-proADM MR-proANP hs-cTnT ST2 
HR (p) HR (95%CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Variable - 0.99 (0.85, 1.15) 0.849 1.81 (1.16, 2.84), 0.009 0.84 (0.65, 1.08), 0.169 1.20 (0.98, 1.48), 0.075 1.31 (1.04, 1.65), 0.024 
LVEF per 5%  <50 
BMI per unit <30 
Age per 10 year 
Sex (female) 
Diabetes 
HF 2y 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PAD 
log Lymphocytes 
HbA1c 
COPD 
Creatinine 
log RDW 
Hemoglobin 
Urate 
log Bilirubin 
log BNP 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002 
1.01 (0.93, 1.08), 0.906 
1.06 (1.02, 1.10), 0.002 
1.43 (1.21, 1.68), < 0.001 
0.94 (0.71, 1.24), 0.646 
1.01 (0.71, 1.44), 0.950 
1.11 (0.85, 1.44), 0.458 
1.31 (1.00, 1.70), 0.046 
0.99 (0.93, 1.05), 0.627 
1.09 (0.80, 1.49), 0.594 
1.02 (0.94, 1.10), 0.721 
1.01 (0.76, 1.34), 0.972 
1.46 (1.12, 1.89), 0.005 
1.68 (1.20, 2.35), 0.003 
0.80 (0.57, 1.12), 0.188 
0.66 (0.48, 0.91), 0.011 
1.19 (1.05, 1.35), 0.005 
1.26 (0.96, 1.66), 0.093 
1.00 (1.00, 1.01), 0.302 
1.50 (0.66, 3.41), 0.336 
0.94 (0.87, 1.01), 0.087 
1.79 (0.68, 4.69), 0.237 
1.34 (1.03, 1.73), 0.028 
1.27 (1.09, 1.47), 0.002 
1.02 (0.94, 1.10), 0.68 
1.07 (1.03, 1.11), < 0.001 
1.37 (1.16, 1.62), < 0.001 
0.90 (0.68, 1.18), 0.431 
0.96 (0.67, 1.37), 0.820 
1.11 (0.85, 1.45), 0.448 
1.23 (0.94, 1.61), 0.126 
0.99 (0.93, 1.046), 0.658 
1.15 (0.85, 1.56), 0.376 
1.02 (0.94, 1.11), 0.605 
1.00 (0.75, 1.33), 1.000 
1.46 (1.13, 1.90), 0.004 
1.60 (1.14, 2.23), 0.006 
0.81 (0.58, 1.12), 0.202 
0.71 (0.52, 0.97), 0.033 
1.19 (1.05, 1.35), 0.005 
1.28 (0.98, 1.68), 0.073 
1.00 (1.00, 1.00), 0.701 
1.32 (0.57, 3.03), 0.520 
0.96 (0.89, 1.03), 0.229 
1.10 (0.40, 3.00), 0.850 
1.28 (0.99, 1.66), 0.061 
1.19 (1.02, 1.39), 0.026 
1.01 (0.94, 1.09), 0.817 
1.06 (1.02, 1.103), 0.002 
1.43 (1.22, 1.683), < 0.001 
0.94 (0.72, 1.242), 0.677 
1.01 (0.71, 1.442), 0.945 
1.10 (0.84, 1.436), 0.478 
1.30 (1.00, 1.693), 0.048 
0.99 (0.93, 1.044), 0.620 
1.08 (0.79, 1.473), 0.620 
1.02 (0.94, 1.104), 0.666 
1.02 (0.77, 1.357), 0.894 
1.47 (1.13, 1.903), 0.004 
1.66 (1.18, 2.317), 0.003 
0.80 (0.58, 1.124), 0.202 
0.66 (0.48, 0.907), 0.010 
1.18 (1.05, 1.338), 0.007 
1.27 (0.97, 1.664), 0.085 
1.00 (1.00, 1.006), 0.136 
1.51 (0.67, 3.429), 0.325 
0.94 (0.87, 1.011), 0.093 
1.79 (0.69, 4.639), 0.229 
1.33 (1.03, 1.723), 0.030 
1.36 (1.14, 1.63), < 0.001 
1.00 (0.92, 1.08), 0.945 
1.06 (1.02, 1.10), 0.002 
1.38 (1.17, 1.62), < 0.001 
0.97 (0.73, 1.28), 0.808 
0.97 (0.68, 1.38), 0.847 
1.11 (0.85, 1.44), 0.457 
1.27 (0.98, 1.65), 0.076 
0.98 (0.93, 1.04), 0.507 
1.12 (0.82, 1.53), 0.467 
1.01 (0.93, 1.10), 0.788 
1.00 (0.75, 1.33), 0.981 
1.46 (1.13, 1.89), 0.004 
1.64 (1.18, 2.30), 0.004 
0.81 (0.58, 1.13), 0.213 
0.66 (0.48, 0.90), 0.010 
1.19 (1.05, 1.34), 0.006 
1.25 (0.95, 1.63), 0.114 
1.00 (1.00, 1.00), 0.578 
1.46 (0.64, 3.33), 0.373 
0.94 (0.88, 1.02), 0.128 
1.49 (0.57, 3.91), 0.419 
1.32 (1.02, 1.71), 0.034 
1.24 (1.06, 1.44), 0.006 
1.00 (0.93, 1.08), 0.936 
1.06 (1.02, 1.10), 0.002 
1.44 (1.22, 1.70), < 0.001 
0.96 (0.73, 1.27), 0.780 
0.99 (0.70, 1.42), 0.967 
1.08 (0.83, 1.41), 0.552 
1.30 (1.00, 1.69), 0.053 
0.98 (0.93, 1.04), 0.522 
1.15 (0.84, 1.57), 0.376 
1.01 (0.93, 1.10), 0.774 
1.00 (0.75, 1.33), 0.987 
1.49 (1.15, 1.93), 0.003 
1.74 (1.24, 2.44), 0.001 
0.80 (0.58, 1.12), 0.200 
0.67 (0.49, 0.92), 0.013 
1.19 (1.05, 1.35), 0.006 
1.28 (0.98, 1.69), 0.073 
1.00 (1.00, 1.00), 0.406 
1.31 (0.57, 3.00), 0.527 
0.94 (0.87, 1.01), 0.092 
1.64 (0.63, 4.26), 0.309 
1.32 (1.02, 1.71), 0.038 
1.25 (1.07, 1.45), 0.004 
C-statistic 0.721 0.721 0.724 0.722 0.723 0.721 
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Appendix Table 1 Continued 
 
 
Base Galectin-3 cFLC hsCRP CystatinC 
HR (p) HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Biomarker - 1.23 (0.86, 1.78), 0.257 1.37 (1.08, 1.74), 0.011 1.21 (1.09, 1.35), < 0.001 1.99 (1.00, 3.98), 0.051 
LVEF per 5% <50 
BMI per unit  <30 
Age per 10 year 
Sex (female) 
Diabetes 
HF 2y 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PVD 
log Lymphocytes 
HbA1c 
COPD 
Creatinine 
log RDW 
Hemoglobin 
Urate 
log Bilirubin 
log BNP 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002- 
1.00 (0.93, 1.08), 0.919 
1.06 (1.03, 1.10), 0.001 
1.41 (1.19, 1.65), < 0.001 
0.92 (0.69, 1.21), 0.536 
1.01 (0.71, 1.43), 0.978 
1.11 (0.85, 1.45), 0.429 
1.31 (1.01, 1.70), 0.045 
0.99 (0.93, 1.05), 0.745 
1.10 (0.81, 1.50), 0.545 
1.01 (0.93, 1.10), 0.767 
1.01 (0.76, 1.34), 0.965 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.79 (0.57, 1.10), 0.166 
0.66 (0.48, 0.91), 0.010 
1.20 (1.06, 1.35), 0.005 
1.26 (0.96, 1.65), 0.096 
1.00 (1.00, 1.00), 0.672 
1.48 (0.65, 3.37), 0.349 
0.94 (0.87, 1.01), 0.090 
1.60 (0.61, 4.20), 0.338 
1.32 (1.02, 1.71), 0.034 
1.27 (1.10, 1.47), 0.002 
1.01 (0.93, 1.09), 0.891 
1.06 (1.02, 1.10), 0.005 
1.38 (1.17, 1.62), < 0.001 
1.01 (0.76, 1.33), 0.961 
0.96 (0.67, 1.37), 0.800 
1.12 (0.86, 1.47), 0.389 
1.30 (1.00, 1.70), 0.048 
0.99 (0.93, 1.05), 0.671 
1.13 (0.83, 1.55), 0.437 
1.02 (0.94, 1.11), 0.635 
0.99 (0.74, 1.31), 0.920 
1.49 (1.15, 1.94), 0.003 
1.62 (1.16, 2.27), 0.005 
0.78 (0.56, 1.08), 0.136 
0.65 (0.47, 0.90), 0.009 
1.19 (1.05, 1.35), 0.006 
1.27 (0.97, 1.66), 0.087 
1.00 (1.00, 1.00), 0.971 
1.43 (0.63, 3.24), 0.387 
0.95 (0.88, 1.03), 0.186 
1.57 (0.60, 4.11), 0.354 
1.35 (1.04, 1.74), 0.023 
1.27 (1.09, 1.47), 0.002 
1.01 (0.94, 1.09), 0.776 
1.07 (1.03, 1.11), < 0.001 
1.44 (1.22, 1.69), < 0.001 
1.00 (0.76, 1.32), 0.990 
0.98 (0.69, 1.39), 0.903 
1.14 (0.87, 1.49), 0.333 
1.24 (0.96, 1.62), 0.104 
0.99 (0.93, 1.05), 0.720 
1.15 (0.84, 1.57), 0.379 
1.01 (0.93, 1.09), 0.847 
1.01 (0.76, 1.34), 0.939 
1.55 (1.19, 2.01), 0.001 
1.66 (1.18, 2.32), 0.003 
0.78 (0.56, 1.08), 0.136 
0.69 (0.50, 0.95), 0.021 
1.19 (1.05, 1.34), 0.006 
1.20 (0.92, 1.58), 0.185 
1.00 (1.00, 1.01), 0.270 
1.24 (0.53, 2.90), 0.615 
0.95 (0.88, 1.02), 0.140 
1.53 (0.59, 3.95), 0.383 
1.41 (1.09, 1.83), 0.009 
1.24 (1.07, 1.44), 0.005 
1.00 (0.93, 1.08), 0.923 
1.06 (1.02, 1.10), 0.002 
1.37 (1.17, 1.62), < 0.001 
0.89 (0.67, 1.18), 0.420 
0.98 (0.69, 1.40), 0.912 
1.07 (0.82, 1.40), 0.622 
1.30 (1.00, 1.69), 0.049 
0.99 (0.93, 1.05), 0.743 
1.11 (0.82, 1.51), 0.506 
1.02 (0.94, 1.10), 0.724 
0.97 (0.73, 1.30), 0.850 
1.47 (1.13, 1.90), 0.004 
1.60 (1.14, 2.24), 0.006 
0.81 (0.58, 1.13), 0.206 
0.67 (0.49, 0.93), 0.015 
1.20 (1.06, 1.36), 0.003 
1.26 (0.96, 1.66), 0.092 
1.00 (0.99, 1.00), 0.404 
1.38 (0.60, 3.15), 0.450 
0.94 (0.87, 1.01), 0.089 
1.27 (0.46, 3.48), 0.644 
1.38 (1.07, 1.79), 0.015 
1.27 (1.09, 1.47), 0.002 
C-statistic  0.721 0.725 0.727 0.724 
 
 35 
 
 
Appendix Table 2: Multivariable analysis with dichotomized values 
 
 
 
 
 
 
 
 
 
 
Base Copeptin MR-proADM  MR-proANP  hsTnT  ST2  
HR (p) HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Biomarker - 1.06 (0.80, 1.40), 0.711 1.40  (1.00, 1.95), 0.052 0.98 (0.72 1.33), 0.879 1.48 (1.11, 1.99), 0.008 1.29 (0.99, 1.68), 0.060 
LVEF per 5% <50 
BMI per unit <30 
Age per 10 year 
Sex (female) 
Diabetes 
HF 2y 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PAD 
log Lymphocytes 
HbA1c 
COPD 
Creatinine 
log RDW 
Hemoglobin 
Urate 
log Bilirubin 
log BNP 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002 
1.00 (0.93, 1.08), 0.918 
1.06 (1.02, 1.10), 0.002 
1.42 (1.20, 1.67), < 0.001 
0.94 (0.72, 1.24), 0.674 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.461 
1.30 (1.00, 1.69), 0.049 
0.99 (0.93, 1.05), 0.646 
1.09 (0.80, 1.49), 0.568 
1.01 (0.94, 1.10), 0.735 
1.01 (0.76, 1.34), 0.943 
1.45 (1.12, 1.88), 0.005 
1.67 (1.19, 2.33), 0.003 
0.80 (0.57, 1.12), 0.194 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.006 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.373 
1.46 (0.64, 3.35), 0.368 
0.94 (0.87, 1.01), 0.087 
1.71 (0.65, 4.49), 0.280 
1.33 (1.03, 1.73), 0.030 
1.26 (1.09, 1.47), 0.002 
1.01 (0.93, 1.08), 0.895 
1.06 (1.02, 1.10), 0.002 
1.38 (1.17, 1.62), < 0.001 
0.92 (0.70, 1.21), 0.556 
1.00 (0.70, 1.42), 0.998 
1.11 (0.85, 1.45), 0.442 
1.27 (0.98, 1.65), 0.075 
0.99 (0.93, 1.05), 0.705 
1.12 (0.82, 1.52), 0.489 
1.02 (0.94, 1.10), 0.673 
1.01 (0.76, 1.35), 0.925 
1.47 (1.13, 1.91), 0.004 
1.63 (1.16, 2.27), 0.004 
0.79 (0.56, 1.10), 0.159 
0.68 (0.49, 0.93), 0.016 
1.18 (1.04, 1.33), 0.010 
1.29 (0.99, 1.70), 0.064 
1.00 (1.00, 1.00), 0.638 
1.33 (0.58, 3.07), 0.502 
0.95 (0.88, 1.02), 0.135 
1.24 (0.45, 3.45), 0.677 
1.32 (1.02, 1.71), 0.035 
1.24 (1.07, 1.44), 0.004 
1.01 (0.93, 1.09), 0.897 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.68), < 0.001 
0.94 (0.71, 1.24), 0.654 
1.01 (0.71, 1.44), 0.948 
1.11 (0.85, 1.44), 0.462 
1.31 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.633 
1.09 (0.80, 1.49), 0.587 
1.02 (0.94, 1.10), 0.720 
1.01 (0.76, 1.34), 0.953 
1.46 (1.12, 1.89), 0.005 
1.67 (1.19, 2.34), 0.003 
0.80 (0.57, 1.12), 0.193 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.006 
1.27 (0.97, 1.66), 0.087 
1.00 (1.00, 1.01), 0.286 
1.49 (0.65, 3.38), 0.344 
0.94 (0.87, 1.01), 0.089 
1.77 (0.68, 4.58), 0.242 
1.34 (1.03, 1.73), 0.029 
1.27 (1.08, 1.50), 0.004 
1.01 (0.93, 1.09), 0.873 
1.06 (1.02, 1.10), 0.003 
1.38 (1.18, 1.63), < 0.001 
0.97 (0.74, 1.28), 0.837 
1.01 (0.71, 1.44), 0.952 
1.09 (0.83, 1.42), 0.541 
1.26 (0.97, 1.64), 0.086 
0.98 (0.93, 1.04), 0.493 
1.09 (0.80, 1.48), 0.593 
1.01 (0.93, 1.10), 0.783 
0.96 (0.72, 1.28), 0.775 
1.42 (1.09, 1.84), 0.009 
1.67 (1.19, 2.33), 0.003 
0.80 (0.57, 1.12), 0.180 
0.66 (0.48, 0.91), 0.010 
1.16 (1.02, 1.31), 0.019 
1.25 (0.96, 1.65), 0.103 
1.00 (1.00, 1.00), 0.544 
1.39 (0.61, 3.18), 0.434 
0.94 (0.88, 1.02), 0.125 
1.41 (0.54, 3.69), 0.487 
1.30 (1.00, 1.68), 0.049 
1.24 (1.07, 1.44), 0.004 
1.01 (0.93, 1.09), 0.875 
1.06 (1.02, 1.10), 0.003 
1.43 (1.21, 1.68), < 0.001 
0.93 (0.71, 1.23), 0.630 
1.00 (0.70, 1.42), 0.988 
1.08 (0.83, 1.41), 0.556 
1.31 (1.00, 1.70), 0.047 
0.98 (0.93, 1.04), 0.584 
1.12 (0.82, 1.53), 0.475 
1.01 (0.93, 1.10), 0.794 
1.00 (0.75, 1.33), 0.996 
1.46 (1.13, 1.89), 0.004 
1.69 (1.21, 2.36), 0.002 
0.82 (0.58, 1.14), 0.236 
0.67 (0.49, 0.92), 0.014 
1.19 (1.05, 1.35), 0.006 
1.26 (0.96, 1.66), 0.092 
1.00 (1.00, 1.00), 0.420 
1.34 (0.59, 3.08), 0.485 
0.94 (0.87, 1.01), 0.088 
1.73 (0.67, 4.49), 0.261 
1.32 (1.02, 1.71), 0.036 
1.25 (1.08, 1.45), 0.003 
C-statistic 0.721 0.722 0.722 0.722 0.723 0.722 
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Appendix Table 2 Continued 
 
 
Base Galectin-3  cFLC  HS CRP  Cystatin C 
HR (p) HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Biomarker - 1.21 (0.90, 1.62), 0.208 1.64 (1.22, 2.19), < 0.001 1.43 (1.10, 1.84), 0.007 1.13 (0.81, 1.57), 0.484 
LVEF per 5%  < 50 
BMI per unit < 30 
Age per 10 year 
Sex (female) 
Diabetes 
HF 2y 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PAD 
log Lymphocytes 
HbA1c 
COPD 
Creatinine 
log RDW 
Hemoglobin 
Urate 
log Bilirubin 
log BNP 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002 
1.01 (0.93, 1.09), 0.881 
1.06 (1.03, 1.10), 0.001 
1.40 (1.19, 1.65), < 0.001 
0.92 (0.70, 1.21), 0.543 
1.01 (0.71, 1.43), 0.977 
1.11 (0.85, 1.45), 0.427 
1.30 (1.00, 1.69), 0.049 
0.99 (0.93, 1.05), 0.746 
1.10 (0.81, 1.50), 0.557 
1.01 (0.93, 1.10), 0.805 
1.01 (0.76, 1.34), 0.968 
1.44 (1.11, 1.87), 0.006 
1.67 (1.20, 2.34), 0.003 
0.79 (0.56, 1.10), 0.161 
0.67 (0.49, 0.92), 0.013 
1.19 (1.06, 1.35), 0.005 
1.27 (0.96, 1.66), 0.090 
1.00 (1.00, 1.00), 0.508 
1.50 (0.66, 3.43), 0.333 
0.94 (0.87, 1.01), 0.090 
1.53 (0.58, 4.06), 0.390 
1.32 (1.02, 1.71), 0.034 
1.27 (1.10, 1.48), 0.001 
1.01 (0.93, 1.09), 0.871 
1.06 (1.02, 1.10), 0.002 
1.35 (1.15, 1.59), < 0.001 
1.00 (0.76, 1.32), 1.000 
0.95 (0.67, 1.36), 0.794 
1.14 (0.87, 1.49), 0.333 
1.31 (1.01, 1.70), 0.044 
0.99 (0.94, 1.05), 0.802 
1.15 (0.84, 1.57), 0.386 
1.01 (0.93, 1.10), 0.748 
1.01 (0.76, 1.35), 0.924 
1.55 (1.19, 2.01), 0.001 
1.60 (1.15, 2.24), 0.006 
0.79 (0.57, 1.10), 0.166 
0.66 (0.48, 0.90), 0.010 
1.18 (1.05, 1.34), 0.007 
1.26 (0.96, 1.65), 0.094 
1.00 (1.00, 1.00), 0.776 
1.39 (0.61, 3.14), 0.435 
0.95 (0.88, 1.02), 0.163 
1.47 (0.56, 3.83), 0.434 
1.33 (1.03, 1.72), 0.028 
1.27 (1.09, 1.47), 0.002 
1.01 (0.93, 1.09), 0.855 
1.07 (1.03, 1.11), < 0.001 
1.43 (1.21, 1.68), < 0.001 
0.99 (0.75, 1.31), 0.966 
0.99 (0.69, 1.41), 0.947 
1.13 (0.87, 1.48), 0.361 
1.25 (0.96, 1.62), 0.102 
0.99 (0.94, 1.05), 0.747 
1.14 (0.83, 1.55), 0.425 
1.01 (0.93, 1.09), 0.840 
1.02 (0.76, 1.35), 0.916 
1.50 (1.16, 1.95), 0.002 
1.63 (1.17, 2.29), 0.004 
0.78 (0.56, 1.09), 0.150 
0.68 (0.50, 0.93), 0.016 
1.19 (1.05, 1.34), 0.006 
1.23 (0.93, 1.61), 0.144 
1.00 (1.00, 1.01), 0.290 
1.36 (0.59, 3.13), 0.468 
0.95 (0.88, 1.02), 0.150 
1.70 (0.66, 4.42), 0.273 
1.39 (1.08, 1.81), 0.012 
1.24 (1.07, 1.44), 0.004 
1.01 (0.93, 1.09), 0.865 
1.06 (1.02, 1.10), 0.002 
1.40 (1.19, 1.66), < 0.001 
0.93 (0.71, 1.23), 0.603 
1.00 (0.70, 1.42), 0.988 
1.09 (0.84, 1.43), 0.516 
1.30 (1.00, 1.69), 0.050 
0.99 (0.93, 1.05), 0.686 
1.09 (0.80, 1.49), 0.568 
1.01 (0.94, 1.10), 0.737 
1.01 (0.76, 1.34), 0.945 
1.46 (1.13, 1.90), 0.004 
1.65 (1.18, 2.31), 0.004 
0.80 (0.57, 1.12), 0.192 
0.67 (0.48, 0.92), 0.012 
1.19 (1.05, 1.35), 0.006 
1.27 (0.97, 1.67), 0.084 
1.00 (1.00, 1.01), 0.502 
1.46 (0.64, 3.34), 0.366 
0.94 (0.87, 1.01), 0.100 
1.59 (0.59, 4.29), 0.363 
1.35 (1.04, 1.75), 0.025 
1.26 (1.09, 1.46), 0.002 
C-statistic 0.721 0.722 0.729 0.724 0.721 
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Appendix Table 3: Combinations of elevated biomarkers when 3 or more elevated 
 
 
 
MR-proADM hsTnT hsCRP cFLC ST2 Number of 
patients (%) 
  X   X X 1 (0.4%) 
X     X X 1 (0.4%) 
    X X X 3 (1.2%) 
  X X X X 4 (1.6%) 
  X X   X 4 (1.6%) 
  X X X   5 (2.0%) 
X   X   X 7 (2.8%) 
X   X X X 8 (3.2%) 
X X     X 15 (6.1%) 
X X   X X 19 (7.7%) 
X   X X   20 (8.1%) 
X X X   X 23 (9.3%) 
X X X     26 (10.5%) 
X X   X   31 (12.6%) 
X X X X X 31 (12.6%) 
X X X X   49 (19.8%) 
230 (93.1%) 208 (84.2%) 180 (72.9%) 172 (69.7%) 116 (47.0%)  
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Appendix Table 4: Full multivariable analysis with number of elevated biomarkers 
 
 HR (95% CI) p HR (95% CI) p 
1 elevated 
2 elevated 
e  3 elevated 
 
LVEF per 5% decrease < 50 
BMI per unit decrease < 30 
Age per 10 year 
Sex (female) 
Diabetes 
HF 2y 
NYHA III/IV 
SBP per 10 mmHg 
LBBB 
HR per 10bpm 
Peripheral edema 
Previous MI 
Current smoker 
PAD 
log Lymphocytes 
HbA1c 
COPD 
Creatinine 
log RDW 
Hemoglobin 
Urate 
log Bilirubin 
log BNP 
 
1.02 (0.63, 1.65), 0.938 
1.35 (0.82, 2.20), 0.235 
2.20 (1.37, 3.54), 0.001 
1.00 (0.93, 1.08), 0.911 
1.06 (1.02, 1.10), 0.002 
1.42 (1.21, 1.67), < 0.001 
0.94 (0.71, 1.24), 0.657 
1.01 (0.71, 1.44), 0.954 
1.11 (0.85, 1.44), 0.458 
1.30 (1.00, 1.70), 0.047 
0.99 (0.93, 1.05), 0.635 
1.09 (0.80, 1.49), 0.582 
1.01 (0.94, 1.10), 0.730 
1.01 (0.76, 1.34), 0.960 
1.46 (1.12, 1.89), 0.005 
1.67 (1.20, 2.34), 0.003 
0.80 (0.57, 1.12), 0.189 
0.66 (0.48, 0.91), 0.012 
1.19 (1.05, 1.35), 0.005 
1.27 (0.97, 1.66), 0.088 
1.00 (1.00, 1.01), 0.287 
1.49 (0.65, 3.39), 0.343 
0.94 (0.87, 1.01), 0.087 
1.76 (0.68, 4.56), 0.244 
1.34 (1.03, 1.73), 0.029 
1.27 (1.09, 1.47), 0.002 
1.02 (0.94, 1.10), 0.686 
1.06 (1.02, 1.10), 0.005 
1.35 (1.15, 1.60), < 0.001 
0.98 (0.75, 1.30), 0.903 
0.99 (0.69, 1.42), 0.963 
1.06 (0.81, 1.39), 0.650 
1.21 (0.92, 1.57), 0.168 
0.99 (0.93, 1.05), 0.667 
1.22 (0.89, 1.66), 0.225 
1.01 (0.93, 1.10), 0.746 
0.97 (0.73, 1.29), 0.840 
1.49 (1.15, 1.93), 0.003 
1.59 (1.14, 2.23), 0.007 
0.79 (0.57, 1.11), 0.172 
0.71 (0.52, 0.97), 0.032 
1.14 (1.01, 1.30), 0.036 
1.26 (0.96, 1.66), 0.091 
1.00 (1.00, 1.00), 0.828 
1.03 (0.44, 2.42), 0.939 
0.95 (0.88, 1.02), 0.161 
1.01 (0.37, 2.73), 0.992 
1.34 (1.03, 1.73), 0.686 
1.21 (1.04, 1.40), 0.005 
0.721 0.730 
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Appendix Table 5: Clinical characteristics according to number of biomarkers elevated 
 
Variable All subjects (n=628) 0 elevated (n=130) 1 - 2 elevated (n=251) 3+ elevated (n=247) P-value 
Demographic Characteristics      
Age (years) 70.82 (10.62) 65.8 (11.9) 70.2 (10.5) 74.1 (8.7) < 0.001  
Sex (Male) 367 (58.4) 67 (51.5) 134 (53.4) 166 (67.2) 0.002 
Current smoker 137 (21.8%) 29 (22.3%) 58 (23.1%) 50 (20.2%) 0.733 
Heart Failure Status      
Previous diagnosis HF 273 (43.5) 39 (30.0) 100 (39.8) 134 (54.3) <0.001 
HF >2 years 194 (30.9%) 26 (20.0%) 69 (27.5%) 99 (40.1%) < 0.001 
NYHA III / IV (v I/II) 208 (33.1%) 25 (19.2%) 73 (29.1%) 110 (44.5%) < 0.001  
LVEF 40.1 (12.1)] 42.3 (11.3) 39.5 (12.8) 39.5 (11.7) 0.068 
LVEF (<50) 466 (77.4%) 87 (70.2%) 190 (79.2%) 189 (79.4%) 0.096 
Peripheral oedema 421 (67.0%) 59 (45.4%) 164 (65.3%) 198 (80.2%) < 0.001 
Medical History      
MI 285 (45.4%) 47 (36.2%) 110 (43.8%) 128 (51.8%) 0.012  
Hypertension 404 (64.3%) 67 (51.5%) 159 (63.3%) 178 (72.1%) < 0.001 
Diabetes mellitus 195 (31.1%) 19 (14.6%) 78 (31.1%) 98 (39.7%) < 0.001 
AF 334 (53.2%) 57 (43.8%) 124 (49.4%) 153 (61.9%) 0.001 
COPD 177 (28.2%) 34 (26.2%) 68 (27.1%) 75 (30.4%) 0.609 
PAD 102 (16.2%) 13 (10.0%) 41 (16.3%) 48 (19.4%) 0.056  
Physiological measurements      
HR 77.1 (15.6) 78.6 (15.6) 77.7 (15.3) 75.7 (15.8) 0.171  
SBP 130.9 (23.4) 130.8 (21.4) 131.0 (23.1) 131.0 (24.8) 0.995  
DBP 67.8 (13.2) 69.6 (12.9) 68.8 (13.3) 65.8 (13.2) 0.009  
BMI 28.6 (6.7) 27.8 (6.1) 28.8 (6.7) 28.9 (7.0) 0.253 
LBBB 120 (19.1%) 18 (13.8%) 53 (21.1%) 49 (19.8%) 0.214 
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Values are mean (SD) or N (%). P-values from one-way ANOVA or Fisher test  
